Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

被引:0
作者
Robert W. Chen
Joycelynne M. Palmer
Sarah Tomassetti
Leslie L. Popplewell
Jessica Alluin
Pritsana Chomchan
Auayporn P. Nademanee
Tanya Siddiqi
Ni-Chun Tsai
Lu Chen
Fay Zuo
Rosemarie Abary
Ji-lian Cai
Alex F. Herrera
John J. Rossi
Steven T. Rosen
Stephen J. Forman
Larry W. Kwak
Leona A. Holmberg
机构
[1] City of Hope National Medical Center,Department of Hematology/Hematopoietic Cell Transplantation
[2] City of Hope National Medical Center,Department of Information Sciences
[3] Beckman Research Institute of the City of Hope National Medical Center,Department of Molecular and Cellular Biology
[4] City of Hope National Medical Center,Clinical Trial Office
[5] Kaiser Permanente Southern California Bone Marrow Transplantation Program,Judy and Bernard Briskin Center for Multiple Myeloma Research
[6] City of Hope National Medical Center,Toni Stephenson Lymphoma Center, Department of Hematology/Hematopoietic Cell Transplantation
[7] City of Hope National Medical Center,Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine
[8] University of Washington,undefined
来源
Journal of Hematology & Oncology | / 11卷
关键词
Bortezomib; Rituximab; CCND1; MRD; Mantle cell lymphoma; Auto-HCT;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 193 条
[1]  
Dreyling M(2005)Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network Blood 105 2677-2684
[2]  
Lenz G(2002)Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study Leukemia 16 587-593
[3]  
Hoster E(2012)Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur Br J Haematol 158 355-362
[4]  
Van Hoof A(2013)CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte Blood 121 48-53
[5]  
Gisselbrecht C(2015)Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma Ann Oncol 26 2323-2328
[6]  
Schmits R(2017)Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma N Engl J Med 377 1250-1260
[7]  
Metzner B(2012)Treatment of older patients with mantle-cell lymphoma N Engl J Med 367 520-531
[8]  
Truemper L(2017)Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab Biol Blood Marrow Transplant 23 1861-1869
[9]  
Reiser M(2018)Total body irradiation is safe and similarly effective as chemotherapy-only conditioning in autologous stem cell transplantation for mantle cell lymphoma Biol Blood Marrow Transplant 24 282-287
[10]  
Steinhauer H(2005)Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma J Clin Oncol 23 676-684